Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2217/imt-2020-0136 http://scihub22266oqcxt.onion/10.2217/imt-2020-0136 32546029!7319491!32546029     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Immunotherapy 2020 ; 12 (15): 1121-1126 Nephropedia Template TP {{tp|p=32546029|t=2020. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019 |pdf=|usr=}}{{32546029}} gab.com Text Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019 JO: Immunotherapy http://www.kidney.de/pget.php?&tw=1&pmid=32546029 #FOAvip Background: Coronavirus disease 2019 (COVID-19) is a novel disease associated with a cytokine-mediated, severe, acute respiratory syndrome. Tocilizumab and lenzilumab are recombinant monoclonal antibodies against IL-6 and granulocyte macrophage colony-stimulating factor, respectively, and have been proposed as a potential treatment for acute, hypoxic respiratory failure associated with COVID-19. Results & methodology: We present the case of a 68-year-old man with COVID-19 who was initially treated with hydroxychloroquine and lenzilumab, but continued to develop hypoxemia, requiring an increase in respiratory support with an associated rise in serum inflammatory markers. He was subsequently treated with tocilizumab with marked clinical improvement and a decrease in acute phase reactants within 48 h. Discussion & conclusion: This case demonstrates the effective use of tocilizumab in the treatment of COVID-19 and suggests the superiority of tocilizumab over lenzilumab in the management of this cytokine-mediated syndrome. Twit Text FOAVip Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019 ????Immunotherapy http://www.kidney.de/pget.php?&tw=1&pmid=32546029 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32546029 #FOAvip English Wikipedia <ref>{{Cite pmid|32546029}}</ref> Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019 #MMPMID32546029 Melody M; Nelson J; Hastings J; Propst J; Smerina M; Mendez J; Guru P Immunotherapy 2020[Oct]; 12 (15): 1121-1126 PMID32546029show ga Background: Coronavirus disease 2019 (COVID-19) is a novel disease associated with a cytokine-mediated, severe, acute respiratory syndrome. Tocilizumab and lenzilumab are recombinant monoclonal antibodies against IL-6 and granulocyte macrophage colony-stimulating factor, respectively, and have been proposed as a potential treatment for acute, hypoxic respiratory failure associated with COVID-19. Results & methodology: We present the case of a 68-year-old man with COVID-19 who was initially treated with hydroxychloroquine and lenzilumab, but continued to develop hypoxemia, requiring an increase in respiratory support with an associated rise in serum inflammatory markers. He was subsequently treated with tocilizumab with marked clinical improvement and a decrease in acute phase reactants within 48 h. Discussion & conclusion: This case demonstrates the effective use of tocilizumab in the treatment of COVID-19 and suggests the superiority of tocilizumab over lenzilumab in the management of this cytokine-mediated syndrome. |Aged[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Combined Modality Therapy[MESH] |Coronavirus Infections/drug therapy/pathology/*therapy[MESH] |Cytokine Release Syndrome/pathology/therapy[MESH] |Granulocyte-Macrophage Colony-Stimulating Factor/antagonists & inhibitors[MESH] |Humans[MESH] |Male[MESH] |Pandemics[MESH] |Pneumonia, Viral/pathology/*therapy[MESH] |Receptors, Interleukin-6/antagonists & inhibitors[MESH] |Respiratory Insufficiency/pathology/therapy[MESH] |SARS-CoV-2[MESH]Case report: use of lenzilumab and tocilizumab for the treatment of co(epmc).pdf DeepDyve Pubget Overpricing